Stock Market Reviews

DYN (Dyne Therapeutics, Inc.) News

Get the latest news, insights, and market updates on DYN (Dyne Therapeutics, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Dyne Therapeutics Shares Rise After Announcing Positive Topline Results for z-rostudirsen in Phase 1/2 DMD Trial
  Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the high short interest stocks to buy right now. On December 8, Dyne Therapeutics announced positive topline results from the Registrational Expansion Cohort of its Phase 1/2 DELIVER trial. The trial is evaluating zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in individuals with Duchenne muscular dystrophy/DMD amenable to […]
  Dec 11, 2025 - $DYN
• Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
  WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the closing of its previously announced upsized underwritten public offering of 21,827,549 shares of its common stock at a public offering price of $18.44 per share, which includes 2,847,071 shares issued upon the exercise in full by the underwriters of their
  Dec 11, 2025 - $DYN
• Why Dyne Therapeutics Stock Was a Big Winner on Wednesday
  The company is attracting much investor attention this week because of what happened in the lab.
  Dec 10, 2025 - $DYN
• Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday Ahead of Fed's Policy Decision
  The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.1% and the actively tr
  Dec 10, 2025 - $DYN
• Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock
  WALTHAM, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an upsized underwritten public offering of 18,980,478 shares of its common stock at a public offering price of $18.44 per share. The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and offering
  Dec 10, 2025 - $DYN
• Amazon initiated, GE Vernova upgraded: Wall Street's top analyst calls
  Amazon initiated, GE Vernova upgraded: Wall Street's top analyst calls
  Dec 10, 2025 - $DYN
• Why Dyne Therapeutics Stock Tanked on Tuesday
  Investors were haunted by the specter of share dilution.
  Dec 9, 2025 - $DYN
• Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets
  A biotech specialist doubled down on Dyne ahead of a clinical readout that drew up investor fanfare — and the timing may be the entire story.
  Dec 9, 2025 - $DYN
• Dyne to seek accelerated approval of DMD drug on Phase I/II data
  Dyne Therapeutics intends to submit a biologics licence application to the FDA for accelerated approval in Q2 2026.
  Dec 9, 2025 - $DYN
• Dyne Therapeutics (DYN) Climbs 9.5% on Stellar Results for DMD Therapy Candidate
  We recently published 10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs. Dyne Therapeutics, Inc. (NASDAQ:DYN) is one of the best performers on Monday. Dyne Therapeutics jumped by 9.47 percent on Monday to finish at $22.20 apiece as investors cheered the encouraging results from its ongoing clinical trial to test the efficacy of […]
  Dec 9, 2025 - $DYN